Key points are not available for this paper at this time.
Objectives: The Personalized Induction Therapy-1 (PIT-1) trial is a multicenter, randomized, phase 2 selection design study in which patients with stage IIIA (N2) non-squamous non-small cell lung cancer received pemetrexed plus cisplatin with bevacizumab or concurrent thoracic radiotherapy, both followed by surgery. Herein, we report the 5-year survival outcomes. Methods: Eighty-two patients (42 in the bevacizumab arm and 40 in the radiotherapy arm) received induction therapy, and 75 patients (38 and 37, respectively) underwent surgery. Five-year overall survival and progression-free survival were compared between arms in the 82 eligible patients. In addition, overall survival, relapse-free survival, and patterns of postoperative relapse were analyzed in the 75 patients who underwent surgery. Results: = .01). All patients with relapse in the PIT-1 trial (except 1 patient in the radiotherapy arm) received at least 1 subsequent therapy. Conclusions: Five-year survival outcomes did not differ between treatment arms. The radiotherapy arm exhibited sufficient local control within the irradiated field.
Takamochi et al. (Mon,) studied this question.